Display options
Cite
Li WX, Zhang SQ, Zhao YD, et al. [Study progress on chemical compounds, pharmacological action and clinical application of Naoxintong capsule]. Zhongguo Zhong Yao Za Zhi. 2018;43(10):1998-2005doi: 10.19540/j.cnki.cjcmm.20180208.004.
Li, W. X., Zhang, S. Q., Zhao, Y. D., Tang, J. F., Li, C. X., Wang, X. Y., & Li, X. L. (2018). [Study progress on chemical compounds, pharmacological action and clinical application of Naoxintong capsule]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 43(10), 1998-2005. https://doi.org/10.19540/j.cnki.cjcmm.20180208.004
Li, Wei-Xia, et al. "[Study progress on chemical compounds, pharmacological action and clinical application of Naoxintong capsule]." Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica vol. 43,10 (2018): 1998-2005. doi: https://doi.org/10.19540/j.cnki.cjcmm.20180208.004
Li WX, Zhang SQ, Zhao YD, Tang JF, Li CX, Wang XY, Li XL. [Study progress on chemical compounds, pharmacological action and clinical application of Naoxintong capsule]. Zhongguo Zhong Yao Za Zhi. 2018 May;43(10):1998-2005. doi: 10.19540/j.cnki.cjcmm.20180208.004. Chinese. PMID: 29933662.
Copy Download .nbib Format: NLM
Share it on

Zhongguo Zhong Yao Za Zhi. 2018 May;43(10):1998-2005. doi: 10.19540/j.cnki.cjcmm.20180208.004.

[Study progress on chemical compounds, pharmacological action and clinical application of Naoxintong capsule].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica

[Article in Chinese]
Wei-Xia Li, Shu-Qi Zhang, Yi-Dan Zhao, Jin-Fa Tang, Chun-Xiao Li, Xiao-Yan Wang, Xue-Lin Li

Affiliations

  1. The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China.
  2. Henan University of Chinese Medicine, Zhengzhou 450046, China.
  3. Henan University, Kaifeng 475000, China.

PMID: 29933662 DOI: 10.19540/j.cnki.cjcmm.20180208.004

Abstract

Naoxintong capsule (NXTC) is an oral Chinese preparation produced by modern technology, derived from the classic preparation of Buyang Huanwu decoction which was recorded by WANG Qing-ren (Qing dynasty) in Yilingaicuo Juanxia Tanweilun. NXTC is composed of 16 herbs including insect herbs and some blood circulation herbs, with the effects of supplementing Qi and activating blood circulation, dispersing blood stasis and dredging collaterals. In clinical application, it is mainly used for stroke, cerebral infarction, vascular dementia, ischemic cerebrovascular disease, transient ischemic attack, coronary heart disease, angina pectoris, ischemic cardiomyopathy, diabetic cardiomyopathy, myocardial infarction, chronic heart failure, chronic complications of diabetes, essential hypertension, hyperlipidemia and other cardiovascular and cerebrovascular diseases, and has achieved good therapeutic effect on above diseases or their concurrent diseases. Its clinical efficacy is mainly achieved through the improvement in related links of brain protection, neuroprotection, cardioprotection, hemorheology, et al. Nearly 200 chemical constituents identified in NXTC are important pharmacological basis for its functions. At present, however, most of its pharmacological basic researches are focused on plant herbs, and the three kinds of insect herbs remain to be further studied. The researches on clinical effectiveness are more comprehensive; the safety study of long-term application in real world is ongoing by our team, and its results are yet to be published after finishing the study. Through the systematic and comprehensive combing and elaboration of the research progresses on the chemical compositions, pharmacological action and clinical application of NXTC, it can provide a reference for the in-depth study of this preparation, with a great significance for the quality control, secondary development and internationalization promotion of NXTC.

Copyright© by the Chinese Pharmaceutical Association.

Keywords: Naoxintong capsule ; cardiovascular diseases ; cerebrovascular diseases ; material bases

Conflict of interest statement

The authors of this article and the planning committee members and staff have no relevant financial relationships with commercial interests to disclose.

Substances

MeSH terms

Publication Types